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Abstract: Maternal folate supplementation is critical for fetal development. Women with MTHFR (methylenetetrahydrofolate 
reductase) gene polymorphisms may not be getting the proper folate form to support fetal development. The objectives of this review 
were to: (1) undertake a comprehensive review on the association of MTHFR polymorphisms with the risk for various congenital 
diseases and other adverse pregnancy outcomes, (2) assess the efficacy and safety of current folic acid and other supplementations in 
women with the MTHFR polymorphism, and (3) provide guidance on the appropriate supplementation for women of childbearing 
potential with the MTHFR gene polymorphism in order to decrease these adverse pregnancy outcomes. Our assessments show that 
women with MTHFR gene polymorphism cannot efficiently convert folic acid to L-5-methyl-tetrahydofolate, the predominant active 
form of folic acid, due to reduced MTHFR enzymatic activity. L-5-methyl-tetrahydrofolate is currently commercially available under 
several brand names. Based on our comprehensive review and knowledge of the biochemistry of the folates, we recommend that 
L-5-methyltetrahydrofolate be given in combination with folic acid to women with MTHFR polymorphism that are pregnant or 
planning to become pregnant. Further study is needed to determine the optimal dose.  
 
Key words: MTHFR (methylenetetrahydrofolate reductase) polymorphisms, maternal health, folic acid, birth defects, pregnancy 
outcomes, homocysteine, L-5-methlyl-THF (L-5-methytetrahydrofolate). 
 
1. Introduction

 
Low folate status is a known risk factor for adverse 
pregnancy and fetal outcomes such as neural tube 
defects. The WHO (world health organization) has 
recently established a guideline on the optimal red 
blood cell folate levels in women of childbearing 
potential in order to prevent NTDs (neural tube defects) 
[1, 2]. Synthetic folic acid, available in supplement 
form is currently the standard intervention for women 
who are pregnant or planning to become pregnant. The 
US (United States) Preventive Services Task Force and 
American Academy of Family Physicians recommend 
that all women of childbearing age or women planning 
to be pregnant take 0.4-0.8 mg/day of folic acid as a 
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supplement [3]. Higher doses of folic acid are 
recommended for women with an increased risk for 
having NTD affected pregnancy. However, people 
with certain genetic single nucleotide polymorphisms 
(e.g. methylenetetrahydrofolate reductase gene 
polymorphism) cannot fully covert synthetic folic acid 
into the active forms and therefore may not fully 
benefit from this supplementation [4, 5]. Although the 
US Preventive Services Task Force has listed 
mutations in folate-related enzymes as one of the risk 
factors for NTDs and the WHO guideline has 
documented that MTHFR (methylenetetrahydrofolate 
reductase) gene polymorphism is associated with low 
folate levels, there is no guideline on folate 
supplementation specific to women of reproductive age 
with MTHFR gene polymorphisms. The purpose of 
this manuscript is to: 1) give an overview of folic acid 
and other folates and how the human body utilizes 
D 
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them, 2) undertake a comprehensive review on the 
association of MTHFR gene polymorphisms with the 
risk for various congenital diseases and other adverse 
pregnancy outcomes, 3) examine the efficacy of 
current folic acid and other supplementations in 
women with the MTHFR polymorphism, and 4) 
provide guidance on the appropriate supplementation 
in order to decrease congenital diseases and adverse 
pregnancy outcomes in women of childbearing 
potential and expecting mothers with the MTHFR gene 
polymorphism. 
1.1 Folate and Folic Acid: What Is the Difference? 
Folates are essential in biochemical reactions and 
serve as cofactors in processes that involve one-carbon 
transfer [6]. Folate is a general name given to 
structurally-related water soluble vitamins (also known 
as vitamin B9, Fig. 1) and includes THF 
(tetrahydrofolate), 5-10-methylene-THF (5, 
10-methylenetetrahydrofolate), L-5-methyl-THF 
(L-5-methyltetrahydrofolate) and 10-formyl-THF 
(10-formyltetrahydrofolate). The 10-formyl-THF and 
5-10-methylene-THF are used in the synthesis of 
purines and pyrimidines, respectively while the 
L-5-methyl-THF serves as a methyl donor in the 
conversion of homocysteine to methionine [7, 8]. Folic 
acid is a synthetic form of folate and is the most 
oxidized form. Since natural dietary folates are 
unstable and found to lose activity during harvesting, 
storage and processing [9], a synthetic version (folic 
acid) was once essential. Folic acid is more stable than 
naturally occurring dietary folates and therefore the 
main form used in vitamin supplements and in food 
fortification [9, 10]. In the body, folic acid is converted 
by the catalytic action of dihydrofolate reductase to 
THF, which is used as a precursor for the formation of 
the active folates; 5-10-methylene-THF, 
L-5-methyl-THF and 10-formyl-THF. Natural dietary 
and cellular folates exist as polyglutamates (where R = > 
1 glutamic acid residue, see Fig. 1) [9]. The 
polyglutamate forms have low absorption, therefore 
dietary folates undergo deconjugation to the 
monoglutamate form (R = OH, Fig. 1) in the gut before 
absorption. On the other hand, synthetic folic acid is 
available only as monoglutamate and thus has higher 
bioavailability than the natural dietary folates. 
 
 
Fig. 1  Folic acid and the most common natural folates: monoglutamate forms, R = OH; polyglutamatate forms, R = > 1 
glutamic acid residues.  
5,10--methylene-THF (4)
Folic acid (1)
10-formyl-THF (3)
THF (2) 
5-L-Methyl-THF (5)
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1.2 Methylenetetrahydrofolate Reductase Gene 
Polymorphisms and Its Effects on Folate Metabolism 
and Folate-Based Biochemical Reactions 
The MTHFR (methylenetetrahydrofolate reductase) 
gene encodes MTHFR, an enzyme that catalyzes the 
synthesis of L-5-methyl-THF from 
5-10-methylene-THF [11]. The normal MTHFR allele 
encodes a fully functional MTHFR enzyme. Many 
genetic SNPs (single nucleotide polymorphisms) of the 
MTHFR gene have been identified, but the MTHFR 
C677T and A1298C variations are the most common 
[12-15]. Each individual has two copies of the MTFHR 
gene, one inherited from each parent. An individual can 
either be heterozygous (SNP in one copy of the gene) 
or homozygous (SNP in both copies of the genes) in the 
MTHFR gene. It is also possible for some individuals 
to present with a compounded heterozygous 
polymorphism, which is one SNP located at two 
different parts of the MTHFR gene (MTHFR 677CT 
/1298AC) [16, 17]. 
The C677T polymorphism is a missense mutation on 
exon 4. Cytosine which is normally found at position 
677 is replaced with a thymine residue and this results 
in valine being substituted for alanine [12, 18]. The 
homozygous polymorphism (C677TT) reduces 
enzymatic activity by 70%, while the heterozygous 
polymorphism (C677CT) results in approximately 35% 
reduction of enzymatic activity [7]. The A1298C 
polymorphism results from a single nucleotide change 
at exon 7 where adenosine is replaced by cytosine and 
as a result glutamate is substituted for alanine. The 
homozygous polymorphism (A1298CC) results in 
about 40% reduction in enzymatic activity while the 
compounded heterozygous polymorphism 
(C677CT/A1298AC) has been shown to decrease 
enzymatic activity by 40%-50% [4]. Hence, MTHFR 
gene polymorphism leads to reduction in enzyme 
activity, which results in lower levels of 
L-5-methyl-THF.  
Since L-5-methyl-THF serves as a methyl donor in 
the conversion of homocysteine to methionine, 
deficiencies in the enzymatic activity of MTHFR leads 
to elevated homocysteine and low methionine levels. 
This is important because further biochemical reactions 
are disrupted as methionine is conjugated with 
adenosine to form SAMe (S-adenosylmethionine). 
SAMe is then used as a methyl donor in the 
methylation of lipids, hormones, nucleic acids (DNA 
and RNA) and myelin basic proteins. In summary, 
MTHFR gene polymorphism can cause low 
methionine levels, which may lead to low SAMe levels 
and improper methylation of DNA and other 
biomolecules [15, 19-22]. 
1.3 Populations Affected 
Both C677T and A1298C MTHFR gene 
polymorphisms have shown variation within different 
ethnic groups. A HuGE review by Botto and Yang 
published in 2000 reported on the MTHFR gene 
polymorphisms by ethnicity and geographic area [23]. 
According to this review, Hispanics seem to have the 
highest rate of C677T polymorphisms with up 21% 
reportedly homozygous (677TT). European whites 
were second with rates from 8-18%. Ireland and Britain 
have had high rates of neural tube defects and their 
reported rate of C677TT homozygous polymorphism 
was 11-13%. Asians were next with reports of about 11% 
frequency of C677TT homozygous polymorphism and 
blacks were lowest at 1%-2%. The A1298C 
polymorphism is not as well documented as the C677T 
polymorphism. The A1298CC homozygous 
polymorphism was found to be approximately 9% 
based on studies in the Netherlands and Canada. The 
compounded heterozygous populations 
(C677T/A1298C) were estimated to be about 15 % in 
Canada, 17% in US and 20% in Netherlands [23]. 
Esfahani et al studied the prevalence of MTHFR 
polymorphism in different ethnic groups and also 
found the 677TT to be highest in Mexican woman and 
lowest in African American women. This was also the 
finding for the compounded heterozygous genotype 
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with Mexican and white women having the highest 
prevalence and Asian and African American women, 
the lowest. The study also found the A1298CC 
homozygous polymorphism to be highest in white 
women [24].  
1.4 Folate Status in Pregnancy  
Maternal folate metabolism and levels plays an 
important role in fetal development and having a 
healthy baby
 
[12, 25, 26].
 
Many studies have examined 
the association of folate metabolism and levels with 
fetal and maternal health. Pregnant women are at high 
risk for folate deficiency due to the increase of folate 
requirements for fetal growth [19]. Reduced MTHFR 
enzymatic activity can cause low serum folate levels, 
elevated homocysteine levels and decrease methylation 
of DNA, proteins, lipids and hormones [16, 19, 27]. 
Homocysteine levels less than 13 µmol/L is normal, 
levels between 13 to 60 µmol/L is moderate, and > 60 
µmol/L is considered severely elevated [16]. High 
homocysteine levels and folate deficiency could affect 
development of ovarian follicle, fertilization, as well as 
formation and development of the embryo [21]. Due to 
the inability to properly process folate, pregnant 
woman with MTHFR gene polymorphisms have an 
increased risk for many deleterious defects, such as 
having a baby with NTDs (neural tube defects), 
congenital heart disease and cardiac septal effects, 
down syndrome, cleft palate, omphalocele, attention 
deficit hyperactivity disorder and low birth weight as 
well as pregnancy loss, preeclampsia, 
pregnancy-associated osteoporosis and susceptibility 
to arsenic toxicity in pregnancy. 
2. Association of MTHFR Gene 
Polymorphism with Congenital Diseases and 
Other Adverse Pregnancy Outcomes 
2.1. Neural Tube Defects  
NTDs (Neural tube defects) are a group of severe, 
disabling and deadly congenital disorders of the 
nervous system, arising from incomplete neural tube 
closure during early stages of pregnancy [28-30]. 
Anencephaly, SB (spina bifida), encephalocele, 
craniorachischisis and iniencephaly are the most 
common [31-33]. There are several types of SB but 
MM (myelomeningocele) commonly accounts for 90% 
of cases [34]. Most infants with NTDs usually die 
within days after birth or struggle with lifelong 
disabilities [29, 32, 34, 35]. The incidence of NTDs 
ranges from 1.0 to 10.0 per 1,000 births depending on 
the country [30]. In the US (United States), the 
prevalence of NTDs such as SB has decreased due to 
FDA (food and drug administration) mandated 
fortification of folic acid in enriched flours and grain 
products [34, 35]. After fortification, SB in the US has 
decreased by approximately 22.9% from 2.62 to 2.02 
per 10,000 births [36]. Although this has been effective, 
still 2,500 live births are affected by NTDs every year 
[32]. 
NTDs occur more frequently in Irish and Mexican 
populations compared to other Caucasians and Asians 
[34, 37]. Other studies have also reported high 
prevalence in China [27]. The pathogenesis of NTDs is 
unknown and is caused by multiple factors such as 
genetics, nutritional deficiencies, and environmental 
determinants [29, 30]. Several studies have found 
positive association between the common MTHFR 
gene C677T polymorphism and risk of NTDs. The 
MTHFR gene 677TT genotype has been associated 
with a 4-fold increase risk of having a child with a NTD 
[38]. Interestingly, to date there are few studies that 
have extensively investigated the association between 
A1298C polymorphism and NTDs [39]. MTHFR gene 
C677T and A1298C polymorphisms result in 
decreased MTHFR enzymatic activity, which increases 
homocysteine levels and DNA hypomethylation [27, 
40].  
A case control study in Setif, Algeria found higher 
homocysteine levels in MTHFR 677TT homozygous 
mothers with spina bifida children than in mothers of 
healthy children (P = 0.06) [38]. Although this is not 
statistically significant the P-value is close to 0.05. The 
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same study also found an increased risk of NTDs in the 
elevated homocysteine mothers (24%) versus control 
(4.9%, P = 0.046) [38]. These observations therefore 
support the hypothesis that elevated homocysteine 
levels are commonly found in mothers with MTHFR 
677TT genotype, which indicates an increased risk of 
having a child with a NTD. A study conducted in 
Mexico examining the risk of anencephaly in 
association to folate, vitamin B12, homocysteine and 
MTHFR gene polymorphism reported that mothers 
with MTHFR 677TT genotype of anencephaly children 
had significantly lower serum folate levels (8.2 ng/mL) 
compared with mothers of healthy controls (14.1ng/mL, 
P = 0.004) [37]. A review conducted by N. Greene et al. 
also examined several studies that investigated the 
association of MTHFR gene polymorphisms and NTDs 
[41]. Pooled results from the studies demonstrated that 
MTHFR 677TT genotype was strongly associated with 
NTDs and there was no significant association between 
the A1298C polymorphism and risk of NTDs. Thus, 
mothers with MTHFR gene C677TT homozygous 
polymorphisms seem to be more at risk of having a 
child with NTDs compared to the other genotypes. 
However, a study in a Turkish population showed that 
MTHFR gene A1298C polymorphism might be 
associated with development of NTDs [39]. 
Although the exact mechanism is not known, 
research indicates that global DNA hypomethylation in 
fetal brain is associated with the pathogenesis of NTDs. 
DNA hypomethylation can alter normal repression or 
expression of genes during fetal development [42]. 
Very few epidemiological studies have investigated the 
association of DNA hypomethylation and risk of NTDs. 
A case control study done in China, found positive 
association between DNA hypomethylation in fetal 
brain tissue and risk of NTD affected pregnancies [27]. 
This study reported that out of the 65 NTD affected 
embryos (case), 8 cases resulted in craniorachischisis, 
16 with anencephaly and open spina bifida, 14 with 
encephalocele, 23 with open spina bifida and four 
fetuses with spina bifida occulta. After stratification, 
the study found that MTHFR 677CT heterozygous and 
MTHFR 677 TT homozygous cases have lower DNA 
methylation levels compared to healthy control fetuses 
[27]. The study also found that the 677CC genotype 
cases had similar DNA methylation levels to that of the 
controls. Another case-control study conducted in two 
populations (Dutch Caucasians and 
Mexican-Americans in Texas) found significant 
association between hypomethylation and the risk of 
NTD in fetuses and very young children in the Dutch 
Caucasian study group but not in the 
Mexican-American study group [40]. The study found 
an absolute decrease of MTHFR DNA methylation by 
0.33% in the Dutch Caucasian children with SB 
compared to controls (P = 0.001) [40]. Therefore, more 
epidemiological studies need to be conducted to better 
understand the association between impaired DNA 
methylation and risk of NTDs in humans.  
2.2 Congenital Heart Disease 
CHD (congenital heart defects) are common birth 
defects that often result from abnormal development of 
the heart during the first 6 weeks of pregnancy [43, 44]. 
CHD is one of the major causes of infant death and 
illnesses [45]. Heart diseases in infants mainly include 
ASD (atrial septal defect), VSD (ventricular septal 
defect), PDA (patent ductus arteriosus), and other types. 
The majority of CHDs are affected by both genetic and 
environmental factors.  
In recent studies, plasma homocysteine level has 
been shown to be elevated in CHD infants, which 
might be a possible risk factor for CSD (cardiac septal 
defects). A genetic variance in MTHFR is one possible 
cause of elevated plasma homocysteine. The impaired 
ability to process folate leads to the inability to convert 
homocysteine to methionine. Several theories exist for 
the mechanism by which elevated homocystiene levels 
can lead to CHD. One study suggested that high 
concentration of homocysteine was found to induce 
electrical remodeling of ion channels in human atrial 
cells that include potassium channels. The remodeling 
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of potassium currents has been hypothesized to induce 
cardiac arrhythmias [46]. Other studies indicated that 
hyperhomocystenimia causes interstitial and 
perivascular fibrosis resulting in increased  
myocardial stiffness, thereby affecting the pump 
function of the myocardium, which then causes heart 
failure [47]. 
Knowing that a genetic variance in the MTHFR gene 
can lead to elevated homocysteine levels, several 
studies have examined the direct association between 
MTHFR gene C677T and A1298C polymorphism and 
the development of CHD in infants and children. 
Another case control study conducted in China that 
investigated mothers of 57 children with congenital 
heart disease of ASD, PDA or both versus 104 control 
mothers, found that maternal MTHFR gene C677TT 
homozygous polymorphism was associated with high 
risk of PDA and ASD in offsprings [48]. A study 
conducted in Canada looked at the relationship of 
A1298CC homozygous polymorphism and congenital 
heart diseases of ventricular septal defect and aortic 
valve stenosis. It was demonstrated that maternal 
MTHFR 1298AC heterozygous genotype was 
associated with increased risk for aortic valve stenosis. 
However, this study also reported mixed results on 
negative association between 677TT genotype and 
congenital heart defects [49].  
CHD is caused by multiple factors including both 
genetic and nongenetic factors. The pathophysiology 
of CHD is complex and a single factor such as the 
MTHFR gene polymorphism cannot explain the whole 
cause. Although elevated homocysteinemia is observed 
in populations with congenital heart diseases such as 
cardiac septal defects, elevated homocysteine level is 
not the only factor contributing to the pathophysiology. 
Further studies need to be conducted in women with 
MTHFR gene polymorphism and elevated 
homocysteine to determine how proper folate 
supplementation can affect maternal health and the 
health of the offspring in terms of congenital heart 
disease.  
2.3 Down Syndrome 
DS (down syndrome) also known as trisomy 21 is a 
chromosomal disease that is associated with growth 
and mental retardation [50, 51]. DS results from an 
over-expression of three extra copies of the gene on 
chromosome 21 causing failure of normal 
chromosomal separation during meiosis [21, 51, 52]. 
DS affects approximately 1 in 1000 to 1100 live births 
worldwide and 1 out of every 700 newborns in the US 
[53, 54]. An important risk factor for DS is advanced 
maternal age at the time of conception [51, 52]. 
Women who are 35 years or older are more at an 
increased risk of having a child with DS, however DS 
children have been born to younger mothers [55-58]. 
Studies have shown that mothers of children with DS 
have abnormal folate metabolism, high homocysteine 
and hypomethylation similar to NTDs, which result in 
abnormal gene expression and chromosomal 
segregation [20, 50, 53, 59].  
Zampieri et al. investigated the influence of 12 
genetic polymorphisms including the MTHR C677T 
and A1298C on folate metabolism and risk of DS. The 
MTHFR gene homozygous C677TT or heterozygous 
C677CT polymorphisms was associated with the risk 
of having a DS child (p value 0.0005). This study 
confirmed low serum folate levels in DS mothers (12.2 
ng/mL) compared to control group (14.6 ng/mL) (P = 
0.028) as a maternal risk factor for a child’s 
development of DS [58]. With respect to the impact of 
MTHFR gene polymorphism and folate levels, folate 
concentrations below the 25th percentile were 
associated with presence of either MTHR gene 
C677CT or C677TT polymorphism. This study 
hypothesized that the increased maternal risk of DS 
may be due to the reduction in enzymatic activity of 
MTHFR [58]. Rai et al [56] conducted a study in 
eastern state of India, which genotyped 312 mothers for 
C677T and A1298C polymorphisms. The study 
showed an association between both the C677T and 
A1298C polymorphisms and maternal risk of having 
DS children. The homozygous 677TT genotype was 
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7.6 times higher in the case study mothers compared to 
controls. The distribution of C677T genotypes 
according to age groups revealed that all 12 
homozygous 677TT mothers were aged less than 
31years among the total of 101 mothers aged less than 
31 years. The frequency of homozygous A1298CC 
polymorphism was higher in DS case mothers (22) 
versus control (5) (P = 0.008). All of the young 
mothers with homozygous 677TT genotype had either 
a first or second child born with DS. The study revealed 
the frequencies of the 1298C allele and homozygous 
1298CC genotype to be higher in case mothers (46.6%, 
24.1%) compared to controls (33.5%, 7.1%), 
respectively. (p value 0.003, 0.008) [56]. Like the 
previous study, Rai et al. concluded that 
polymorphisms in MTHR gene results in 
hypomethylation of DNA that could affect various 
cellular functions, such as DNA repair, replication, 
gene expression and chromatin conformation, leading 
to disease conditions. Other epidemiological studies 
have also found strong association between the 
MTHFR 677T allele and risk of DS [17, 20, 52, 59-62]. 
Contrary to the above studies, others have shown that 
there is no association between MTHR polymorphisms 
and risk of DS, therefore further studies are necessary 
[63-65].  
2.4 Cleft Palate 
CL/P (cleft lip with or without cleft palate) is birth 
defect, which happens early during pregnancy where 
baby’s lip or mouth does not form properly. During the 
early pregnancy, a baby’s head forms by the joining of 
body tissue from each side of the head in the center. 
The lip is formed during the fourth and seventh week, 
and the roof of the mouth between the sixth and ninth 
week of pregnancy. If the lip tissues and/or palate 
tissues do not join completely, it results in an opening, 
which is cleft lip and/or cleft palate. According to CDC, 
each year in the United States, about 2,650 babies are 
born with a cleft palate and 4,440 babies are born with 
a cleft lip with or without cleft palate [66]. Both genetic 
and environmental factors are known to play a role in 
the development of CL/P and many studies have been 
conducted to verify the association between two 
functional polymorphisms—C677T and A1298C—in 
the MTHFR gene and an increased risk of CL/P. 
Studies on the association of MTHFR gene 
polymorphism with CL/P were performed in different 
region of the world to find the prevalence among 
subjects with CL/P. In many studies, it has been 
proposed that low periconceptional folate intake 
increases the risk of CL/P in offspring, and this risk is 
even more pronounced in mothers with homozygous 
MTHFR 677TT or 1298CC genotypes. In a study 
performed in 153 patients with nonsyndromic oral 
clefts and 205 control subjects genotyped for 176 
different types of gene SNPs, MTHFR gene 
polymorphism showed evidence of association with 
CL/P [67]. There was a statistically significant 
difference between genotype frequencies of MTHFR 
C677T polymorphisms in non-syndromic CL/P cases 
compared with controls [68]. These and similar studies 
were performed in California, Brazil, Turkey, South 
America, Germany, Poland, Paris, Korea, China, Brazil, 
European and Northern Venezuela population samples. 
MTHFR gene A1298C locus was analyzed and shown 
positive and negative association with the cleft lip and 
palate [15, 69-71]. Despite the association between 
MTHFR C677T polymorphism and CL/P, there still 
needs more studies to be performed to indicate if the 
MTHFR gene polymorphism is the independent 
marker for the CL/P [72-74]. 
2.5 Other Congenital Disease Sand Adverse Pregnancy 
Outcomes 
The MTHFR gene polymorphisms and mutation 
have also been found to be associated with a number of 
other congenital diseases and adverse pregnancy 
outcomes. A recent case report from the New England 
Journal of Medicine describes a boy with microcephaly 
and episodic cyanosis. After a very long differential 
diagnosis the boy was finally diagnosed at 10 months 
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with severe MTHFR deficiency. The boy was treated 
with folinic acid (5-formyl-tetrahydrofolic acid) and 
other active forms of the B vitamins, which resulted in 
clinical and symptomatic improvement. The authors of 
this case identified two novel mutations in the MTHFR 
gene that put the patient at risk of developing 
microcephaly and episodic cyanosis [75]. Other studies 
have been conducted to extensively examine the 
association of MTHFR polymorphisms and other 
congenital diseases such as omphalocele, attention 
deficit hyperactivity disorder, and microcephaly. A 
study conducted on genetic information from all 
newborn births in New York from 1998-1999, found 
significant association between MTHFR 677T allele 
and risk of omphalocele [76]. Other studies have also 
shown strong association between risk of omphalocele 
and MTHFR C677Tpolymorphism [77].  
Homocysteine concentration has been reported to be 
positively associated with the risk of pregnancy 
complications such as low birth weight, increased 
incidence of pregnancy loss, preeclampsia, intrauterine 
growth retardation, and placental infarction [78]. A 
prospective cohort study, which investigated the DNA 
of pregnant women with complications (intrauterine 
fetal death, preeclampsia, preterm delivery, and small 
for gestational age infants) showed significantly higher 
frequency of MTHFR gene C677T polymorphism 
compared to control subjects. This study also showed 
higher frequencies of homozygous 677TT allele than 
the heterozygous 677CT allele. In a subgroup analysis, 
statistically significant increase in MTHFR C677T 
polymorphism was observed in women with small for 
gestational age newborns [78]. In a meta-analysis study 
performed in Caucasian and East Asian populations, 
the MTHFR C677T polymorphism was associated with 
a risk of preeclampsia [79]. In another study performed 
in India, the data showed that MTHFR A1298C 
heterozygous or homozygous genotypes significantly 
increased the risk of recurrent pregnancy loss [80]. 
In a Mendelian randomization study conducted in 
Seoul, Korea, birth weight significantly differed in 
relation to MTHFR C677T genotype. The MTHFR 
homozygous 677TT allele showed lower birth weights 
than the normal 677CC allele. Birth weight also 
decreased as maternal homocysteine level increased 
[81]. According to another study conducted in Mexico 
City, birth weight was 4 g higher for every 100 μg/day 
increase in folate intake; however, neither maternal nor 
infant MTHFR genotype was associated with 
differences of infant weight at birth [82]. A similar 
study conducted in the United Kingdom also showed 
no significant relationship between MTHFR 
polymorphism and low birth weight [83]. Different 
studies demonstrated mixed results on association of 
MTHFR C677T and/or A1298C polymorphism in 
pregnancy outcomes [80, 84, 85]. Thus, it is suggested 
that more studies with large samples be conducted to be 
more conclusive. 
3. Supplementation 
3.1 Folic Acid 
Adequate folate levels are paramount in pregnancy 
for proper fetal development and maternal health. 
There is a large body of evidence supporting the 
protective effects of folic acid in preventing NTDs and 
other adverse pregnancy outcomes such as 
miscarriages and preeclampsia [86]. Folate deficiency 
can result from poor dietary intake or failed 
intracellular retention of folate and leads to elevated 
homocysteine levels that are associated with various 
congenital disorders such as NTDs, specifically spina 
bifida and anencephaly [17]. Although the underlying 
mechanism by which folic acid prevents NTDs is 
widely unknown, many epidemiological studies have 
shown that supplementation of folic acid during the 
periconception period decreases the risk and 
recurrence of NTD-affected pregnancies by 
approximately 4 folds [13]. A four year 
epidemiological study showed a reduction of 50%-70% 
spina bifida cases and 25%-50% anencephaly cases 
with supplementation of 5 mg/week folic acid [87]. It is 
generally recommended that women of childbearing 
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age consume supplements containing at least 0.4-0.8 
mg of folic acid daily to reduce the risk of NTDs. 
However, most experts recommend higher doses of 
folic acid supplements for women at intermediate to 
high risk of having a child with a NTDs. Currently, the 
US Preventive Services Task Force and American 
Academy of Family Physicians recommend that all 
women of childbearing age or women planning to be 
pregnant take 0.4-0.8 mg/day of folic acid as a 
supplement. This recommendation does not apply to 
women who have had previous NTD affected 
pregnancy and women on some antiseizure drugs [3]. 
Certain antiseizure drugs are known to cause folate 
deficiency and higher dose of folic acid is 
recommended for all women of childbearing age and 
pregnant women [88]. Although there has not been any 
study that determined the optimal dose of folic acid for 
women on antiseizure drugs, it is usually recommended 
that women of childbearing potential take 1mg/day of 
folic acid and the dose be increased to 4 mg/day 
following conception [88]. The American College of 
Obstetricians and Gynecologists recommends a folic 
acid supplement of 0.4 mg/day for women at low risk 
of NTDs and 4 mg/day for women at high risk of NTDs 
or who have had a previous pregnancy with an NTD 
[89]. 
While research has indicated that MTHFR gene 
polymorphism is associated with an increased risk for 
neural tube defect, there is no guideline on folic acid 
supplementation specific to women with MTHFR gene 
polymorphism. However, the US Preventive Services 
Task Force has listed mutations in folate-related 
enzymes as one of the risk factors for NTDs and by 
implication women with MTHFR gene polymorphism 
may need to take higher doses of folic acid [3]. 
MTHFR catalyzes the conversion of 5, 
10-methylene-THF to L-5-methyl-THF, one of the 
active forms of folic acid that is used as a one-carbon 
source in the synthesis of methionine from 
homocysteine. MTHFR gene polymorphism reduces 
levels of L-5-methyl-THF and increases homocysteine 
levels [90]. Therefore, plasma homocysteine level is 
used as a sensitive indicator of folate status and 
MTHFR function. Plasma homocysteine levels can 
also increase due to vitamin B6 or B12 deficiency. 
Thus, B12 and B6 deficiency should be ruled out prior 
to utilizing plasma homocysteine level as a biomarker 
for folate status and MTHFR function.  
The effects of folic acid (0.4 mg/day or 0.8 mg/day) 
on homocysteine levels in Chinese hypertensive 
patients with heterozygous C677CT or homozygous 
C677TT polymorphism were assessed. This was done 
in a multicenter, randomized, double-blind control 
study. The results showed that homocysteine levels 
remain high in patients with homozygous C677TT 
polymorphism treated with either 0.4 mg/day or 0.8 
mg/day of folic acid as well as in patients with 
heterozygous C677CT polymorphism treated with 0.4 
mg/day of folic acid [91]. In another large-scale 
population-based double blind trial, the effects of six 
months supplementation of different folic acid doses 
(0.1 mg/day, 0.4 mg/day, 4 mg/day, 4 mg/week) on 
plasma homocysteine levels, plasma folate levels and 
red blood cell folate levels were evaluated [92]. The 
study showed that folic acid dose of 0.1 mg/day and 4 
mg/week given for 6 months did not reduce the high 
homocysteine levels in those women with MTHFR 
homozygous 677TT genotype. Even with the high dose 
of 4 mg/day folic acid supplementation, women with 
MTHFR 677TT genotype showed higher plasma 
homocysteine levels as well as lower plasma and RBC 
folate levels compared to women with the MTHFR 
normal 677CC genotype [92]. In animal model of 
severe MTHFR deficiency, folic acid failed to decrease 
mortality while L-5-methyl-THF reduced mortality by 
31%. Based on these and other studies, high dose of 
folic acid alone may not be sufficient as a supplement 
for women with MTHFR polymorphism and people 
with severe MTHFR deficiency.  
Although folic acid is generally considered safe, 
there are several studies that raise concerns regarding 
its safety. Folic acid is the most oxidized form of the 
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folates and is believed to be metabolized in the 
intestine and the liver to tetrahydrofolic acid and 
subsequently to 5-L-methyl-THF. However, a study 
showed the presence of unmetabolized folic acid in the 
blood and its level was dose-dependent and 
accumulated with repeated exposure [93]. The 
unmetabolized folic acid was associated with reduced 
natural cell cytotoxicity and this effect was greater with 
increased levels of unmetabolized folic acid [94]. High 
folic acid intake was also found to be associated with 
cognitive decline in older people [95]. In addition, 
there are several reports on the association of folic acid 
supplement with certain cancers such as prostate and 
colorectal cancers [96-98]. High dose folic acid may 
also mask Vitamin B12 deficiency by correcting 
macrocytic anemia [99]. The effect of B12 deficiency 
on RBC (macrocytic anemia) can be easily diagnosed 
while the neurological effects may not be identified 
until after the disease has progressed. Vitamin B12 
mainly plays a role in the regeneration of THF and the 
effect of B12 deficiency on RBC can be prevented by 
administering higher dose of folic acid.  
3.2 L-5-Methyltetrahydrofolate 
L-5-methyl-THF (L-5-Methyltetrahydrofolate) is 
the predominant active form of folic acid in the plasma 
and in red blood cells. It is also naturally present in 
dietary sources mostly as polyglutamates [9]. The 
calcium salt of L-5-methyl-THF (L-5-methyl-THF 
calcium), which is also known as levomefolate calcium 
is available as a dietary supplement and is marketed 
under the brand names Deplin [100] and Metafolin. It is 
also available in combination with oral contraceptives 
as Safyral and Beyaz. Each Safyral and Beyaz tablet 
contains 0.451 mg of levomefolate calcium along with 
3 mg of drospirenone. The difference between Safyral 
and Beyaz is in the amount of ethylene estradiol. Both 
Safyral and Beyaz were approved by the FDA in 2010 
and the levomefolate calcium in the contraceptive pills 
was intended to reduce the risk of NTD in a pregnancy 
conceived while taking the contraceptive or soon after 
discontinuation of the contraceptive. The European 
Food Safety Authority Panel also evaluated 
L-5-methyl-THF calcium in 2004 and concluded that 
there is no safety concern when it is used as a source of 
folate in foods and food supplements with a tolerable 
upper level of 1mg/adult/day [101]. In 2013, the 
European Food Safety Authority Panel similarly gave a 
scientific opinion on the safety and bioavailability of 
the glucosamine salt of L-5-methyl-THF 
(L-5-methyl-THF glucosamine) in response to a 
request from the European commission. Based on a 
comparative crossover bioavailability study in human 
volunteers, the panel concluded that L-5-methyl-THF 
glucosamine has similar bioavailability to that of 
L-5-methyl-THF calcium [102]. The panel also came 
to the conclusion that there was no safety concern 
regarding the genotoxicity of L-5-methyl-THF 
glucosamine.  
The approval of L-5-methyl-THF calcium as part of 
a contraceptive by the US FDA and the scientific 
comments by the European Food Safety Authority 
ascertain the safety of L-5-methyl-THF. A number of 
pharmacokinetic and pharmacodynamic studies have 
indicated that L-5-methyl-THF has similar 
bioavailability to that of folic acid and it is at least as 
effective as folic acid in correcting folate status and 
decreasing homocysteine levels [103-106]. An 
epidemiological study compared the effects of a 
prenatal supplement containing 1.13 mg of 
L-5-methyl-THF plus folic acid 0.4 mg with standard 
PNV (prenatal vitamins) containing 0.8 to 1 mg of folic 
acid alone on decreasing the rate of anemia in pregnant 
women. This study found that fewer women developed 
anemia in the prenatal supplement containing 
L-5-methyl-THF and folic acid compared with the 
standard treatment of PNV [86]. In a randomized 
double-blind study involving healthy women of 
childbearing potential, steady-state plasma and RBC 
folate levels were compared following administration 
of oral contraceptives containing either 0.4 mg of folic 
acid or 0.451 mg of levomefolate calcium for 24 weeks 
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[107]. The study results demonstrated that both plasma 
and RBC folate levels were slightly higher in the 
levomefolate group compared to the folic acid group 
during the treatment phase as well as during the 20 
weeks following cessation of treatment [107]. Another 
randomized double-blind study that compared the 
effects of equimolar amounts of L-5-methyl-THF and 
folic acid on RBC folate levels demonstrated that 
L-5-methyl-THF is more effective than folic acid in 
correcting folate status [108]. In a randomized study 
comparing the effects of 0.4 mg of folic acid and 0.412 
mg of L-5-methyl-THF on the pharmacokinetics of 
folate, Prinz-Langenohl et al showed that total plasma 
folate levels and Cmax (the maximum folate 
concentration) were higher and Tmax (the time to peak) 
was shorter in women with homozygous 677TT 
genotype supplemented with L-5-methyl-THF than 
those supplemented with folic acid [109]. 
3.3 Betaine 
Betaine is either obtained from diet or synthesized in 
the body from choline [110]. The recommended 
betaine intake is estimated at 0.5 to 3 grams per day 
[111-113]. Homocysteine is methylated to methionine 
with either betaine or L-5-methyl-THF as the methyl 
donor. Thus, betaine and L-5-methyl-THF are 
interchangeable sources of methyl group in the 
conversion of homocysteine to methionine [110]. The 
reaction that uses betaine as a methyl donor is 
catalyzed by the enzyme BHMT 
(betaine-homocysteine methyltransferase), which is 
located only in the liver and kidney [112, 114, 115]. In 
the liver, BHMT catalyzes up to 50% of homocysteine 
metabolism [112]. Therefore, BHMT regulates 
homocysteine levels in the liver. Epidemiological 
studies have indicated that dietary supplementation 
with betaine may reduce homocysteine levels in 
healthy volunteers and individuals with 
hyperhomocysteinemia [112, 114]. Studies have 
shown that treatment with betaine may reduce the risk 
of consequences of severe MTHFR deficiency [116]. A 
meta-analysis of 15 case reports and case series 
involving 35 patients investigated the effects of betaine 
on survival and psychomotor development in patients 
with severe MTHFR deficiency. The results indicated 
that all five patients who were treated with betaine 
early survived and had normal psychomotor 
development. On the other hand, the 11 patients that 
died were either not treated with betaine or their 
treatment was delayed. None of the remaining 19 
survivors whose treatment was delayed had normal 
psychomotor development. A new born baby with 
MTHFR deficiency was treated with increasing doses 
of betaine for two years and the researchers reported 
that 6 g/day of betaine administered in six divided 
doses resulted in adequate control of homocysteine 
levels [117]. Although physical development was 
normal, language and motor developments were 
delayed by 3-6 months. This study concluded that early 
betaine treatment prevents mortality and allows normal 
psychomotor development in patients with severe 
MTHFR deficiency [116]. Holm and colleagues [118] 
reported that plasma betaine levels are inversely 
associated with plasma total homocysteine levels and 
this is more pronounced in those with C677TT 
homozygous polymorphism and low folate status, 
implying that betaine is an important methyl donor 
especially in those with low folate status and MTHFR 
polymorphism. All the studies indicated that betaine is 
an alternative methyl donor in those with MTHFR 
polymorphism and deficiency. Therefore, betaine can 
be used as add-on supplement for individuals with 
MTHFR polymorphism. 
4. Discussion 
This article presents a comprehensive review on the 
effects of MTHFR gene polymorphism on folate 
metabolism and its association with an increased risk 
for various congenital diseases and other adverse 
pregnancy outcomes. It also examines the 
pharmacodynamic effects and pharmacokinetic 
properties of several supplements that are used to 
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prevent NTDs and other adverse outcomes related to 
folate deficiency or inept folate metabolism. Based on 
our assessment, we will provide a recommendation on 
the supplementation to women of childbearing 
potential with MTHFR gene polymorphism.  
Folates are essential for proper fetal development 
and maternal health. The demand for folates increases 
during pregnancy, therefore folate supplementation is 
necessary. Natural dietary folates are unstable and 
degrade during harvesting, processing, and storage [9]. 
In addition, natural dietary folates exist as 
polyglutamates, which are less absorbable forms. 
Hence, natural dietary folates have to undergo 
deconjugation to monoglutamate forms in the 
gastrointestinal tract before absorption. As a result, 
natural dietary folates have low bioavailability [10]. 
Because of the low bioavailability and stability issues, 
the natural dietary source of folates may not be 
adequate during pregnancy when the demand for 
folates is higher. Folic acid, the synthetic and most 
oxidized form of the folates, is used as supplement and 
in food fortification due its stability and good 
bioavailability [10]. Numerous studies have shown that 
periconceptional folic acid supplementation decreases 
the recurrence of fetal neural tube defects (NTDs) [119, 
120]. Neural tube closes three to four weeks 
postconception. Because the neural tube forms early in 
the pregnancy, at a time when women are not even 
aware of that they are pregnant, and half of the 
pregnancies in the USA are unplanned [119], it is 
recommended that all women of childbearing potential 
take folic acid supplementation. In general, the current 
folic acid recommendation is 0.4-0.8 mg/day for all 
women of child bearing age who are low risk for 
having a fetus with NTD [3]. Higher doses of folic acid 
are recommended for women at higher risk for having 
an NTD affected pregnancy.  
MTHFR gene polymorphism, particularly C677T 
and A1296C have been shown to be associated with an 
increased risk for NTDs and other deleterious 
pregnancy outcomes. Although mutations in folate 
metabolizing enzymes have been recognized as one of 
the risk factors for NTDs [3] and the WHO guideline 
on folate levels [2] has documented that MTHFR 
polymorphism is associated with low folate levels, 
there are no recommendations on folate 
supplementation specific to women with MTHFR 
polymorphism. However, since higher doses of folic 
acid is recommended for women at high risk for having 
NTD affected pregnancy, by implication women with 
MTHFR polymorphism may take high dose of folic 
acid. Homozygous C677TT and A1298CC 
polymorphism as well as compounded heterozygous 
polymorphism (C677CT/A1298AC) have been shown 
to decrease the enzymatic activity of the MTHFR by 
40-70% [4, 5, 121]. MTHFR is a key enzyme that 
catalyzes the synthesis of L-5-methyl-THF from folic 
acid. L-5-methyl-THF is the major active form of 
folates in the plasma and in red blood and serves as 
methyl donor in the synthesis of methionine from 
homocysteine. 
Although current recommendations imply that 
women with MTHFR polymorphism may take high 
dose of folic acid, they may not benefit from high dose 
of folic acid and may even have detrimental effect on 
their health for a number of reasons. People with 
MTHFR polymorphism cannot convert folic acid to 
L-5-methyl-THF efficiently due to the reduced activity 
of the MTHFR enzyme. Therefore, giving more folic 
acid to process for an enzyme that is working at lower 
capacity appears inconsistent with the scientific bases. 
High dose of folic acid has also been found to mask 
B-12 deficiency [99] and has been associated with 
decreased immunity [94] as well as impaired cognition 
[95].  
Currently, the stable form of L-5-methyl-THF is 
available as a calcium salt. L-5-methyl-THF calcium, 
which is also known as levomefolate calcium is 
commercially available under various proprietary 
names. Pharmacokinetic and pharmacodynamic studies 
have shown that the bioavailability of L-5-methyl-THF 
is similar to that of folic acid and it is at least as 
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effective as folic acid in correcting folate status. 
However, in people with MTHFR polymorphism, 
L-5-methyl-THF has been shown to be more effective 
in correcting folate status and reducing homocysteine 
levels [109]. Our comprehensive literature study and 
understanding of the biochemistry of folates and 
folate-based biochemical reactions indicate that a 
combination of L-5-methyl-THF and folic acid would 
be a better choice for women of childbearing potential 
with MTHFR polymorphism. However, a study is 
needed to establish the optimal dose of 
L-5-methyl-THF. L-5-methyl-THF calcium is 
available in various strengths ranging from 0.4 mg to 
15 mg of oral tablets or capsules. The FDA has 
approved oral contraceptives containing 0.451 mg of 
L-5-methyl-THF calcium. The European Food Safety 
Authority Panel has also concluded that there is no 
safety concern when L-5-methyl-THF calcium is used 
as a supplement up to 1 mg/adult/day [101]. Therefore, 
the safety of L-5-methyl-THF calcium at a dose greater 
than 1 mg/day is unknown and requires studies. The 
synthesis of methionine from homocysteine uses either 
betaine or L-5-methyl-THF as a methyl donor. 
Consequently, studies have shown that 
supplementation with betaine reduces the risk of the 
consequence of MTHFR gene polymorphism or severe 
MTHFR deficiency. Therefore, betaine may be added 
to the folic acid supplement in women with MTHFR 
polymorphism. However, at this point we cannot 
recommend betaine in pregnant women due to a lack of 
safety studies. 
5. Conclusion 
MTHFR gene polymorphism is associated with an 
increased risk for a number of birth defects including 
NTDs as well as other adverse pregnancy outcomes. 
Because of the reduced MTHFR enzymatic activity, 
women with MTHFR gene polymorphism cannot get 
the full benefit from high dose of folic acid 
supplementation and even may have detrimental effect 
on their health. Women with a homozygous or 
compounded heterozygous polymorphism are at a 
higher risk of adverse pregnancy outcome due to the 
significant reduction in enzymatic activity. The stable 
form of the end product of MTHFR, L-5-methyl-THF 
is currently available. Pharmacokinetic studies have 
shown that the bioavailability of L-5-methyl-THF is 
similar to that of folic acid. Studies have also 
demonstrated that there is no safety concern when 
L-5-methyl-THF calcium is used up to 1mg/day and it 
is more effective than folic acid at correcting folate 
status in individuals with MTHFR gene polymorphism. 
Therefore, L-5-methyl-THF calcium should be given 
in combination with folic acid to women of 
childbearing potential with MTHFR gene 
polymorphism. However, study is needed to establish 
the optimal dose. L-5-methyl-THF calcium is marketed 
in various strengths ranging from 0.4 mg to 15 mg of 
oral tablets or capsules. The safety of L-5-methyl-THF 
at a dose greater than 1 mg/day/adult is unknown. Thus, 
study is needed to determine the safety profile of 
L-5-methyl-THF at higher doses. Betaine and 
L-5-methyl-THF are interchangeable sources of 
methyl group in the biochemical conversion of 
homocysteine to methionine and alternatively betaine 
may be added to folic acid supplement for women with 
MTHFR polymorphism.  
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